Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | -25.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -88.00K | -50.29K | -28.22K | -30.00 | 0.00 | -286.00 |
EBITDA | -8.41M | -5.47M | -4.50M | -3.42M | -4.14M | -2.55M |
Net Income | -8.69M | -5.53M | -5.00M | -3.56M | -4.52M | -2.55M |
Balance Sheet | ||||||
Total Assets | 6.49M | 1.96M | 4.32M | 8.04M | 11.06M | 879.25K |
Cash, Cash Equivalents and Short-Term Investments | 4.10M | 1.84M | 4.06M | 7.98M | 10.37M | 671.09K |
Total Debt | 4.01M | 0.00 | 0.00 | 344.23K | 318.43K | 1.37M |
Total Liabilities | 10.46M | 942.76K | 655.25K | 1.12M | 1.12M | 2.03M |
Stockholders Equity | -3.97M | 1.01M | 3.67M | 6.92M | 9.94M | -1.15M |
Cash Flow | ||||||
Free Cash Flow | -3.24M | -4.22M | -3.85M | -2.00M | -2.80M | -1.35M |
Operating Cash Flow | -3.24M | -4.22M | -3.70M | -1.99M | -2.80M | -1.35M |
Investing Cash Flow | 943.18K | 2.80M | 4.78M | 1.60M | -9.91M | 0.00 |
Financing Cash Flow | 6.44M | 1.96M | 0.00 | 0.00 | 12.58M | 1.22M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $1.19M | 0.29 | 138.38% | ― | 306.41% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
37 Underperform | $4.67M | ― | -130.35% | ― | ― | ― | |
29 Underperform | $1.13M | ― | -112.65% | ― | ― | 93.34% | |
27 Underperform | $6.17M | ― | -512.79% | ― | ― | 38.86% |
On February 21, 2025, Protagenic Therapeutics Inc. held its 2024 Annual Meeting of Stockholders, where stockholders approved a proposal to reprice certain outstanding stock options under the company’s 2006 and 2016 Equity Incentive Plans. The Board of Directors subsequently repriced these options to an exercise price of $0.2655 per share, aligning with the closing price of the company’s common stock on that date, potentially impacting the company’s financial strategy and stakeholder interests.